Comparative Pharmacology
Head-to-head clinical analysis: AMBODRYL versus LORATADINE REDIDOSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMBODRYL versus LORATADINE REDIDOSE.
AMBODRYL vs LORATADINE REDIDOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antihistamine (H1-receptor antagonist) with anticholinergic and sedative properties.
Selective peripheral H1 receptor antagonist; inhibits histamine release from mast cells.
10-20 mg intramuscularly or intravenously every 4-6 hours as needed, up to a maximum of 80 mg/day.
10 mg orally once daily
None Documented
None Documented
Terminal elimination half-life 12-15 hours in adults; prolonged to 20-30 hours in hepatic impairment.
Terminal elimination half-life is 8–14 hours (mean ~12 hours) for desloratadine (active metabolite); parent loratadine half-life ~3–20 hours (mean ~8 hours). Clinically, once-daily dosing maintains steady state in 5–7 days.
Primarily renal (70-80% as metabolites, 20-30% unchanged); biliary/fecal excretion accounts for 15-20%.
Renal (approximately 40% as metabolites), biliary/fecal (approximately 60% as metabolites). Less than 1% excreted unchanged in urine.
Category C
Category A/B
Antihistamine
Antihistamine